<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00662844</url>
  </required_header>
  <id_info>
    <org_study_id>PR065013</org_study_id>
    <secondary_id>DOD. CDMRP. W81XWH-07-1-0201</secondary_id>
    <nct_id>NCT00662844</nct_id>
  </id_info>
  <brief_title>Vitamin D Supplementation in Younger Women</brief_title>
  <acronym>VITADAS</acronym>
  <official_title>Optimum Vitamin D Nutrition in Young Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Creighton University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Creighton University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      That on average it will require a vitamin D dose of 1700IU/day to increase the serum
      25hydroxyvitamin D level from 20 to 30ng/ml in young Caucasian women and a dose of 1860 to
      2480 IU/day in African American
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vitamin D is a unique nutrient in that its requirement can be met by both endogenous
      production from sun and from diet, which makes it difficult to determine the actual
      requirements as for other nutrients. The current recommended dietary reference intake (DRI)
      for vitamin D is 200 IU for adults between 25- 50 years, 400 IU for adults between 51-70
      years and 600 IU for adults 70 years of age. In view of many scientists in the field of
      vitamin D, the current DRI of vitamin D is too low. This is mainly because of the increase in
      prevalence of vitamin D deficiency observed in the population based on measured serum 25OHD
      levels. It is now recognized that serum 25OHD is an indicator of vitamin D status. There is a
      growing consensus that serum 25OHD concentration of at least 30-32 ng/ml are needed to reduce
      serum Parathyroid hormone (PTH) and reduce bone loss. Also, research over the last two
      decades has provided additional evidence that higher vitamin D levels (25OHD 30ng/ml) are
      necessary for optimum overall health and prevent disease. There is no clear view of the
      amount of vitamin D intake required to maintain the optimum level of serum 25OHD levels in
      the population of all ages and there are no systematic dose response studies of vitamin D in
      women of all ages. A few studies carried out with different sexes and age groups have
      suggested that an untreated subject with a serum 25OHD concentration of 20 ng/ml would need a
      daily dose of ~1700 IU/d of Vitamin D3 to reach a serum 25OHD of 32 ng/ml in Caucasians,
      while in African Americans the Vitamin D3 requirement would be higher - 1860-2480 IU/d.

      The current proposal aims at studying the dose response effect of vitamin D3 400 IU, 800
      IU,1600 IU and 2400 IU or placebo on serum 25OHD and serum PTH in young women with vitamin D
      insufficiency (serum 25OHD &lt;20 ng/ml) and an adequate calcium intake of 1000mg/day.

      Another aim of the study is to establish the minimum effective dose of vitamin D3 which
      Normalizes PTH in Caucasian and African American young women. Vitamin D dose that reduces
      serum PTH to normal level in 97% of normal population is the recommended dietary allowance.

      We will also establish the safety of these higher doses of vitamin D supplementation relating
      to hypercalcemia/hypercalcuria.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum 25hydroxyvitamin D</measure>
    <time_frame>Baseline, Change from Baseline at 6 Months and 12 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Parathyroid hormone</measure>
    <time_frame>Baseline, Change from Baseline at 6 Months and 12 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum and urine calcium</measure>
    <time_frame>Baseline, Change from Baseline at 6 Months, 9 Months and 12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>calcium absorption</measure>
    <time_frame>Baseline, Change from Baseline at 12 Months</time_frame>
    <description>radioactive calcium absorption is measured at baseline and end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone density</measure>
    <time_frame>Baseline, Change from Baseline at 12 Months</time_frame>
    <description>bone density</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>physical performance battery</measure>
    <time_frame>Baseline, Change from Baseline at 12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume FEV1</measure>
    <time_frame>Baseline, Change from Baseline at 12 Months</time_frame>
    <description>spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bone markers</measure>
    <time_frame>Baseline, Change from Baseline at 12 Months</time_frame>
    <description>serum osteocalcin,serum N-telopeptides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum 1,25-dihydroxyvitamin D3</measure>
    <time_frame>Baseline, Change from Baseline at 12 Months</time_frame>
    <description>serum test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>skin color</measure>
    <time_frame>Baseline, Change from Baseline at 6 Months and 12 Months</time_frame>
    <description>measurement of sin color through the study using an IMS smart probe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum 24,25dihydroxyvitamin D</measure>
    <time_frame>Baseline, Change from Baseline at 12 Months</time_frame>
    <description>measurement of serum 24,24(OH)2D by LCMS( liquid chromatography mass spectrophotometry</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">198</enrollment>
  <condition>Hypovitaminosis D</condition>
  <arm_group>
    <arm_group_label>A1 vitamin D3 400IU</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Orally for one year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A2 vitamin D3 800IU</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Orally for one year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A3 vitamin D3 1600IU</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Orally for one year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A4 Vitamin D3 2400 IU</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Orally for one year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for one year</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>vitamin D3</intervention_name>
    <description>Oral, one capsule daily of vitamin D3 (400IU, 800IU, 1600 IU, or 2400IU) plus calcium citrate (1-4 tablets) twice daily to reach a total calcium intake of 1000-1200 mg/day</description>
    <arm_group_label>A1 vitamin D3 400IU</arm_group_label>
    <arm_group_label>A2 vitamin D3 800IU</arm_group_label>
    <arm_group_label>A3 vitamin D3 1600IU</arm_group_label>
    <arm_group_label>A4 Vitamin D3 2400 IU</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Calcium citrate (Citracal)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Premenopausal women, minimum age 25 years, maximum age 45 years. (Women with
             hysterectomy and/or oophorectomy must have a premenopausal FSH level.)

          2. Serum 25OHD level: 5 - 20 ng/ml

          3. BMI &lt; 45 kg/m2.

          4. Willing to discontinue vitamin D supplements after entering the study.

          5. Negative pregnancy test before BMD and calcium absorption tests.

          6. Willing to give signed informed consent form

          7. Subject is Caucasian or African American

        Exclusion Criteria:

          1. Cancer (exceptions: basal cell carcinoma or if cancer occurred more than 10 years ago)
             or terminal illness.

          2. Previous hip fracture.

          3. Hemiplegia.

          4. Uncontrolled type I diabetes Â± significant proteinuria or fasting blood sugar &gt;140 mg
             in type II diabetes.

          5. Kidney stones- &gt; 2 in a lifetime.

          6. Chronic renal failure (serum creatinine &gt;1.4 mg/dl).

          7. Evidence of chronic liver disease, including alcoholism.

          8. Physical conditions such as severe osteoarthritis, rheumatoid arthritis, heart failure
             severe enough to prevent reasonable physical activity.

          9. Previous treatment with bisphosphonates (more that 3 months), PTH or PTH derivatives,
             (e.g. Teriparatide) or Fluoride in the last 6 months.

         10. Previous treatment within the last 6 months with calcitonin or estrogen (except birth
             control pills).

         11. Chronic high dose corticosteroid therapy (&gt; 10 mg/day) for over 6 months and not
             within the last 6 months.

         12. Anticonvulsant therapy. (Dilantin, Phenobarbital)

         13. High dose thiazide therapy (&gt; 37.5 mg).

         14. 24 hour urine calcium &gt; 290 mg on 2 baseline tests.

         15. Serum calcium exceeding upper normal limit on 2 baseline tests.

         16. BMD. T-score less than -3.0 for spine or hip.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J C Gallagher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Creighton University Medical Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Gallagher JC, Kinyamu HK, Fowler SE, Dawson-Hughes B, Dalsky GP, Sherman SS. Calciotropic hormones and bone markers in the elderly. J Bone Miner Res. 1998 Mar;13(3):475-82.</citation>
    <PMID>9525348</PMID>
  </reference>
  <reference>
    <citation>Aloia JF, Talwar SA, Pollack S, Feuerman M, Yeh JK. Optimal vitamin D status and serum parathyroid hormone concentrations in African American women. Am J Clin Nutr. 2006 Sep;84(3):602-9.</citation>
    <PMID>16960175</PMID>
  </reference>
  <reference>
    <citation>Holick MF, Siris ES, Binkley N, Beard MK, Khan A, Katzer JT, Petruschke RA, Chen E, de Papp AE. Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab. 2005 Jun;90(6):3215-24. Epub 2005 Mar 29.</citation>
    <PMID>15797954</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2008</study_first_submitted>
  <study_first_submitted_qc>April 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2008</study_first_posted>
  <last_update_submitted>March 24, 2016</last_update_submitted>
  <last_update_submitted_qc>March 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamin D insufficiency,vitamin D3 treatment,young women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Avitaminosis</mesh_term>
    <mesh_term>Rickets</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

